GlassScriptPhysician profile
Bindu K Sathi
NPI 1093872483
$77,866.91
in general payments reported to CMS, 2019-2025
24 companies · $11K in 2025
The $11K reported for 2025 was more than what 86% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $18.13 · 2021: $14K · 2022: $24K · 2023: $14K · 2024: $14K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Food and Beverage: $738 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,675.00 |
| Food and Beverage | $738.01 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $74,200.00 | 2021-2025 | |
| Global Blood Therapeutics, INC. | $2,206.47 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $319.87 | 2019-2024 | Soliris, Ultomiris |
| Novo Nordisk INC | $262.26 | 2021-2025 | Alhemo |
| Novartis Pharmaceuticals Corporation | $181.63 | 2019-2025 | |
| Shire North American Group INC | $121.86 | 2019 | |
| Pfizer INC. | $71.75 | 2024-2025 | |
| Pharming Healthcare, INC. | $65.79 | 2022-2023 | Ruconest |
| Chiesi USA, INC. | $56.37 | 2022-2025 | Ferriprox |
| Sobi, INC | $50.16 | 2025 | |
| Csl Behring | $39.93 | 2019-2020 | |
| Hema Biologics, LLC | $39.05 | 2022 | |
| Genentech, INC. | $31.89 | 2024 | Hemlibra |
| Rhythm Pharmaceuticals, INC. | $28.84 | 2025 | Imcivree |
| Rare Disease Therapeutics, INC. | $24.82 | 2025 | Xromi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $23.70 | 2024 | Roctavian |
| Apellis Pharmaceuticals, INC. | $21.10 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.27 | 2025 | |
| Jazz Pharmaceuticals INC. | $19.97 | 2019 | |
| Ucb, INC. | $19.00 | 2023 | Fintepla |
| Genetix Biotherapeutics INC | $18.75 | 2023 | |
| Grifols USA, LLC | $15.68 | 2019 | |
| Emmaus Medical, INC. | $15.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bindu Sathi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.